Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Multiple Sclerosis
Data on multiple sclerosis detailed by M. Palesh and co-authors
November 9th, 2008
" There are few studies on the diffusion of expensive new therapies in low- or middle-income countries. The objectives of this study were to describe the diffusion of interferon beta for the treatment of patients with multiple sclerosis (MS) in Iran and to analyze its use in a cohort of 890 patients in Tehran registered in the Iranian MS Society (IMSS) registry," scientists in Stockholm, Sweden report. " Data on the diffusion of interferon beta drugs from 2000 to 2004 in Iran were obtained from the Ministry of Health (MOH). Data on the utilization of interferon beta in selected patient groups were collected from routine clinical data of the IMSS in a sample of...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
